Not FDA approvedSynthetic pentadecapeptideEducation only

BPC-157

Also known as Body protection compound 157, PDA marketing alias

A heavily marketed recovery compound whose consumer use is far ahead of the available human safety evidence.

Action boundaryeducation onlyPrepare for a clinician

Education and decision support. This release does not generate doses, injection instructions, cycles, diagnoses, prescriptions, or vendor pathways.

What it is

Proposed repair and angiogenic pathways are primarily described in preclinical research; a clinically established receptor has not been identified.

Not FDA approvedRegenerative / research

BPC-157

A heavily marketed recovery compound whose consumer use is far ahead of the available human safety evidence.

Education only
ReceptorunknownRoutessubcutaneous, oralConfidencelow

Visible for broad education until a goal is selected.

Not FDA approved; no consumer protocol is provided.

Useful for
  • Understanding why recovery claims remain uncertain
  • Preparing questions when a clinic markets BPC-157
Not established for
  • An executable recovery protocol
  • Self-injection
  • Human dosing
Evidence receipts
Review evidence